TP53 and B-cell chronic lymphocytic leukemia: Moreover, a nationwide Italian analysis based on an administrative dataset from the Italian Medicines Agency (AIFA), including more than 740 patients with CLL with aberrant TP53 treated front-line with ibrutinib, showed 2-year treatment persistence and OS rates of 63% and 83%, respectively [37].